Bio-TechneMEX:TECH 83 Operating Margin % is 24.24% as of Mar. 2026, which is 4% below its 10-year median of 25.18. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,117.60. The stock has 8 warning signs investors should review. Among 944 Biotechnology companies, Bio-Techne ranks better than 90.57% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Bio-Techne's Operating Income for the
three
months ended in Mar. 2026 was MXN1,361 Mil. Bio-Techne's Revenue for the
three
months ended in Mar. 2026 was MXN5,616 Mil. Therefore, Bio-Techne's Operating Margin % for the quarter that ended in Mar. 2026 was 24.24%.
Warning Sign:
Bio-Techne Corp operating margin has been in a 5-year decline. The average rate of decline per year is -2%.
The historical rank and industry rank for Bio-Techne's Operating Margin % or its related term are showing as below:
MEX:TECH'
s Operating Margin % Range Over the Past 10 Years
Min: 19.91 Med: 25.18 Max: 30.38
Current: 24.31
MEX:TECH's Operating Margin % is ranked better than 90.57% of 944
companies
in the Biotechnology industry
Industry Median: -86.83
vs MEX:TECH: 24.31
Bio-Techne's 5-Year Average Operating Margin % Growth Rate was -2.00% per year.
Bio-Techne's Operating Income for the
three
months ended in Mar. 2026 was MXN1,361 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was MXN5,413 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Bio-Techne Operating Margin % Related Terms
Bio-Techne Operating Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TECH vs HALO, IBRX, NUVL: Operating Margin % Comparison
For the Biotechnology subindustry, Bio-Techne's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Bio-Techne's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (MEX:TECH) has a Operating Margin % of 24.24% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Bio-Techne and its competitors. This is near median its historical median of 25.18. Over the past decade, Bio-Techne's Operating Margin % has ranged from 19.91 to 30.38. According to the industry distribution chart, Bio-Techne ranks #89 out of 944 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Bio-Techne's Operating Margin % too high?
Bio-Techne's current Operating Margin % of 24.24% is near median its 10-year median of 25.18. Over the past 10 years, this metric has ranged from a low of 19.91 to a high of 30.38. Based on the distribution chart, Bio-Techne ranks #89 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Operating Margin % compare to HALO and IBRX?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #89 out of 944 companies for Operating Margin %. This places Bio-Techne in the top 9% of its industry — outperforming the majority of peers. Historically, Bio-Techne's own Operating Margin % has ranged from 19.91 to 30.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Bio-Techne and its competitors. Bio-Techne's current Operating Margin % is 24.24%, which is near median its own 10-year median of 25.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current Operating Margin % of 24.24%. The stock's GF Value™ is MXN1,117.60, compared to a current price of MXN1,090.00 — trading 2.5% below its estimated fair value. The current Operating Margin % is 24.24%, which is near median its 10-year median of 25.18. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current Operating Margin % is 24.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 2.5% below its estimated GF Value™ of MXN1,117.60.
Key valuation signals for MEX:TECH:
Operating Margin %: 24.24% (near median its 10-year median of 25.18)
GF Value™: MXN1,117.60 vs. price of MXN1,090.00 (2.5% below fair value)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
